BioAtla Inc (NAS:BCAB)
$ 2.05 0.3 (17.14%) Market Cap: 98.64 Mil Enterprise Value: 5.50 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 36/100

Q1 2022 Bioatla Inc Earnings Call Transcript

May 04, 2022 / 08:30PM GMT
Release Date Price: $4.08 (+6.53%)
Operator

Good day and thank you for standing by. Welcome to the BioAtla first-quarter 2022 financial results and business conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to Bruce Mackle, LifeSci Advisors. Please go ahead.

Bruce Mackle
LifeSci Advisors, LLC - IR

Thank you, operator, and good afternoon, everyone. With me today on the phone are Dr. Jay Short, Chairman, CEO, and Co-Founder; Scott Smith, President; Philippe Martin, Chief of Clinical Development and Operations; Sheri Lydick, Senior Vice President, Commercial Strategy; and Richard Waldron, Chief Financial Officer. Earlier today, BioAtla released financial results and a business update for the quarter ended March 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that statements made during this conference call that are not historical facts or forward-looking statements within the meaning of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot